Clinical Trial Update: Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pasireotide long-acting release to octreotide long-acting release in patients with metastatic carcinoid disease; the study evaluated eff…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Syndrome
• Carcinoid Tumor

Drugs mentioned

• SIGNIFOR LAR (PASIREOTIDE)
• Sandostatin LAR (octreotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Symptomatic Refractory Resistant Carcinoid Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-07-30